The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study
Abstract
Metformin, an insulin-sensitizing drug, has been shown to improve ovarian function and glucose metabolism in obese women with polycystic ovary syndrome (PCOS), but its effects and possible benefits in nonobese PCOS subjects are not well known. Seventeen nonobese (body mass index < 25 kg/m(2)) women with PCOS were randomized to receive either metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months; n = 8) or ethinyl estradiol (EE, 35 microg)-cyproterone acetate (CA, 2 mg) oral contraceptive pills (EE-CA; n = 9). Waist to hip ratio; serum concentrations of sex steroids, glucose, and insulin during a 75-g oral glucose tolerance test; early phase insulin and C-peptide secretion; and insulin sensitivity using a euglycemic hyperinsulinemic clamp were assessed at baseline and at 3 and 6 months of treatment. Metformin did not have any effect on glucose tolerance or insulin sensitivity, but fasting insulin concentrations decreased from 44.4 +/- 5.1 (SE) to 29.8 +/- 4.3 pmol/liter (P = 0.03), the waist to hip ratio decreased from 0.78 +/- 0.01 to 0.75 +/- 0.01 (P = 0.01), and hepatic insulin clearance increased during the treatment. Furthermore, metformin decreased serum testosterone levels from 2.7 +/- 0.3 to 2.0 +/- 0.2 nmol/liter (P = 0.01) and improved menstrual cyclicity. EE-CA did not have any significant effect on glucose tolerance, serum insulin levels, or insulin sensitivity, but it increased slightly the body mass index (P = 0.09) and significantly serum leptin concentrations (P < 0.001) and decreased serum testosterone levels from 2.1 +/- 0.2 to 1.4 +/- 0.2 nmol/liter (P = 0.03). In conclusion, EE-CA seems to be an efficient mode of therapy for hyperandrogenic symptoms associated with PCOS, but its possible negative effects on insulin and glucose metabolism also have to be taken into consideration in nonobese subjects. Metformin improved hyperandrogenism, hyperinsulinemia, and menstrual cyclicity, most likely through its positive effect on insulin clearance and abdominal adiposity. Thus, similarly to obese PCOS women, nonobese PCOS subjects with anovulation may also benefit from metformin treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 1×
“However, because no simultaneous decrease of C-peptide secretion was observed, this finding did not reflect any real decrease in insulin secretion by the -cells, in line with previous data indicating the lack of a direct effect of metformin on insulin secretion (52).”
ResultKiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561
Holte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673399 · Cited by 435
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417 · cited 1×
“However, OCs have been shown to slightly worsen glucose tolerance in healthy women of normal weight (27, 28) as well as in obese PCOS subjects (29).”
BackgroundCellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336
Cited by
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Escobar-Morreale, H. F., Carmina, E., Dewailly, D., Gambineri, A., Kelestimur, F., Moghetti, P., Pugeat, M., Qiao, J., Wijeyaratne, C. N., Witchel, S. F., et al. (2012) · Human Reproduction Update · doi:10.1093/humupd/dmr042 · Cited by 494
“Considering that these drugs induce a reversible menopause requiring combined use with OCPs and its very high economic cost, this class of drugs should be restricted, if used at all, to the very selected patients with severe hyperandrogenism of ovarian origin that do not respond to other drugs.”
ResultInfluentialPalomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Piltonen, T., Morin-Papunen, L., Koivunen, R., Perheentupa, A., Ruokonen, A., & Tapanainen, J. S. (2005) · Human Reproduction · doi:10.1093/humrep/deh850 · Cited by 294
Self-citationPolycystic Ovarian Syndrome: Diagnosis and Management
Sheehan, M. T. (2004) · Clinical Medicine & Research · doi:10.3121/cmr.2.1.13 · Cited by 263
Morin-Papunen, L., Rantala, A. S., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3061 · Cited by 243
Self-citationRubin, K. H., Glintborg, D., Nybo, M., Abrahamsen, B., & Andersen, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01354 · Cited by 195
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197
Palomba, S., Orio, F., Nardo, L. G., Falbo, A., Russo, T., Corea, D., Doldo, P., Lombardi, G., Tolino, A., Colao, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0689 · Cited by 177
Cosma, M., Swiglo, B. A., Flynn, D. N., Kurtz, D. M., LaBella, M. L., Mullan, R. J., Elamin, M. B., Erwin, P. J., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2429 · Cited by 129
Nader, S., & Diamanti-Kandarakis, E. (2007) · Human Reproduction · doi:10.1093/humrep/del407 · Cited by 109
Fraison, E., Kostova, E., Moran, L. J., Bilal, S., Ee, C. C., Venetis, C., & Costello, M. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub3 · Cited by 94
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad465 · Cited by 78
Hirsutism: an evidence-based treatment update
Somani, N., & Turvy, D. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0078-4 · Cited by 69
Tomlinson, J., Millward, A., Stenhouse, E., & Pinkney, J. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02994.x · Cited by 66
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Wu, J., Zhu, Y., Jiang, Y., & Cao, Y. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802217027 · Cited by 52
Use of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Shah, D., Patil, M., & On behalf of the National PCOS Working Group (2018) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_72_18 · Cited by 51
THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0585 · Cited by 49
Zuuren, E. J., & Fedorowicz, Z. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14486 · Cited by 35
Altinok, M. L., Ravn, P., Andersen, M., & Glintborg, D. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1460343 · Cited by 28
Wu, L., Liu, Y., Huang, X., Lin, K., Liu, Y., Li, Z., Wei, T., Song, L., Hua, Y., & Wang, X. (2023) · Clinical Endocrinology · doi:10.1111/cen.14895 · Cited by 17
Baldani, D. P., Skrgatic, L., Ougouag, R., & Kasum, M. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1381681 · Cited by 17
Metadata
- Authors
- Morin-Papunen, L., Vauhkonen, I., Koivunen, R., Ruokonen, A., Martikainen, H., & Tapanainen, J. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-01
- Volume
- 88
- Issue
- 1
- Pages
- 148-156
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2168941094
- Cited by
- 183
- References
- 18
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.